- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Colorectal cancer
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 1667KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 354KB)
Encorafenib – March 2021
Encorafenib: Capsule 50 mg, Capsule 75 mg; Braftovi®
Last updated
16 July 2021